Dr. Braiteh is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3730 S Eastern Ave
Las Vegas, NV 89169Phone+1 702-952-3400Fax+1 702-952-3461
Education & Training
- University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2006 - 2009
- Yale-New Haven Medical CenterResidency, Internal Medicine, 2000 - 2003
- St Joseph's University Medical SchoolClass of 1998
Certifications & Licensure
- OH State Medical License Current
- NV State Medical License 2010 - 2025
- TX State Medical License 2004 - 2025
- MI State Medical License 2009 - 2013
- CT State Medical License 2003 - 2004
Awards, Honors, & Recognition
- Vegas Seven Castle Connolly, 2014
- Desert Companion Castle Connolly, 2011
Clinical Trials
- A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors Start of enrollment: 2011 Mar 01
- Safety Study of PLX108-01 in Patients With Solid Tumors Start of enrollment: 2009 Oct 01
- A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies Start of enrollment: 2011 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- 3 citationsPhase 1b study of pan-AKT inhibitor vevorisertib alone or with paclitaxel or fulvestrant in PIK3CA/AKT/PTEN-mutated advanced solid tumors.Shubham Pant, Erika Hamilton, Susanna V Ulahannan, James F Strauss, Fadi S Braiteh
Cancer. 2023-06-15 - 10 citationsResults from Phase 1 Extension Study Assessing Pexidartinib Treatment in 6 cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCTWilliam D. Tap, Arun S. Singh, Stephen P. Anthony, Mike Sterba, Chao Zhang
Clinical Cancer Research. 2021-10-29 - 2 citationsAssociation of Tumor Mutational Burden and Immune Gene Expression with Response to PD-1 Blockade by Sasanlimab Across Tumor Types and Routes of Administration.Siwen Hu-Lieskovan, Fadi Braiteh, Juneko E. Grilley-Olson, Xiao Wang, Alison Forgie
Targeted Oncology. 2021-10-25
Journal Articles
- Oxford University Press Has Registered This DOI Pre-PublicationFadi Braiteh, MD, Oxford University Press
Press Mentions
- Nab-Paclitaxel plus Gemcitabine Opens up Treatment Options in Pancreatic CancerMarch 16th, 2016
- Nab-Paclitaxel Outduels Paclitaxel in HR+/HER2- and Triple-Negative MBCMarch 12th, 2016
- US Oncology Research Translational Oncology Program Enrolls 2,000February 4th, 2016
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: